Sociedad Española de Neumología y Cirugía Torácica   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1955)

Organization Overview

First Clinical Trial
2004
NCT02209974
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sociedad Española de Neumología y Cirugía Torácica | Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Spain

Active Ingredients

Drugs in Phase 4 Trials (1)

fluticasone (cutivate) (1 trial)

Drugs in Phase 3 Trials (1)

oxygen (1 trial)

Drugs in Phase 2 Trials (1)

reslizumab (cinqair) (1 trial)

Drugs in Other Trials (1)

theophylline (synophylate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Inflammation (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4